drugset / Trial / NCT01586403
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
Phase 1
Active not recruiting
14 enrolled
Loyola University
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
Timeline
- Start
- 2012-07
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 2.5e+06 cells/kg | — |
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 7.5e+06 cells/kg | — |
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 2.5e+07 cells/kg | — |
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 7.5e+07 cells/kg | — |
| Background | IL-2 | Protein / enzyme biologic | — | — |